Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology
Disease Category: Solid Tumors
Trial Information
A Phase 1 Study of STA-9090, Administered Once-Weekly in Patients with Solid Tumors
A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered
Once-Weekly in Patients with Solid Tumors
An open-label dose escalation study of patients with solid
tumors treated with STA-9090
This is a dose-escalation study. The first cohort will consist
of three patients who will receive STA 9090 during a 1-hour
infusion once per week for three consecutive weeks followed by a 1
week dose-free interval. Subsequent cohorts will receive higher
amounts of STA-9090 provided that the previous dose was well
tolerated during cycle 1 (week 1 – 4). Dose escalation will
continue until the maximum tolerated dose (MTD) is determined.
Lee Rosen, MD
Premiere Oncology
Located in:
Santa Monica, CA 90404-2111
Phone: 310-633-8400
Research Center Information: Premiere Oncology
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
